![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase
Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the
SAILING Study
|
|
|
AIDS 2022 Juy 29-Aug 1 Montreal
Ruolan Wang,1 Joe Horton,2 Aditya Joshi,3 Netsanet Gebremedhin,2 Brian Wynne,1 Sandy Griffith,1 Mark Underwood1
1ViiV Healthcare, Durham, NC, USA; 2PAREXEL International, Durham, NC, USA; 3GSK, Bangalore, Ind
![0804221copy](../images/080522/080522-16/0804221copy.gif)
![0804222copy](../images/080522/080522-16/0804222copy.gif)
![0804223copy](../images/080522/080522-16/0804223copy.gif)
![0804224copy](../images/080522/080522-16/0804224copy.gif)
![0804225copy](../images/080522/080522-16/0804225copy.gif)
![0804226copy](../images/080522/080522-16/0804226copy.gif)
![0804227copy](../images/080522/080522-16/0804227copy.gif)
![0804228copy](../images/080522/080522-16/0804228copy.gif)
![0804229copy](../images/080522/080522-16/0804229copy.gif)
![08042210copy](../images/080522/080522-16/08042210copy.gif)
![08042211copy](../images/080522/080522-16/08042211copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|